AnaptysBio Inc logo

AnaptysBio Inc

$ 25.82 +0.04 (+0.16%) 04:00 PM EST
P/E:
At Loss
P/B:
2.64
Market Cap:
$ 734.11M
Enterprise V:
$ 309.84M
Volume:
255.28K
Avg Vol (2M):
359.24K
Also Trade In:
Volume:
255.28K
Market Cap $:
734.11M
PE Ratio:
At Loss
Avg Vol (2-Month):
359.24K
Enterprise Value $:
309.84M
PB Ratio:
2.64

Business Description

Description
AnaptysBio Inc is clinical-stage biotechnology company. It is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company develops product candidates to address emerging biological targets using its proprietary, antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product candidates are ANB020, ANB019, and Checkpoint receptor agonist. The entity generates revenue from the collaborative research and development arrangements.